Skip to content
Parker Institute for Cancer Immunotherapy
Search
Search Close

PICI Network Researchers to Present at 2022 Annual Meeting of Society for Immunotherapy of Cancer #SITC22

Parker Institute for Cancer Immunotherapy (PICI) Network investigators will present the latest in immuno-oncology research at the 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC). The meeting is Nov. 10-12 at the Boston Convention & Exhibition Center, with pre-meeting workshops starting Nov. 8 at Omni Boston Hotel.

The annual conference, billed as the largest in the U.S. focused solely on cancer immunotherapy, will feature nine PICI-led studies this year. They include the McGRAW clinical trial looking at the effects of gut bacteria and a more diverse gut microbiome on the efficacy of checkpoint inhibitors, a type of immunotherapy treatment.

Members of the PICI network of preeminent academic and medical institutions also will discuss the development of personal vaccines, as well as the application of what has been learned from past results in combination therapy studies to future treatments, and will present the results of studies on immunotherapy-induced immune response and other research.

“The Parker Institute for Cancer Immunotherapy and our affiliated investigators and collaboration partners are dedicated to developing safer, more effective treatments for patients through the pursuit of bold, transformative clinical research,” said Ute Dugan, MD, PhD, PICI’s chief medical officer. “By highlighting this work at SITC, we aim to demonstrate a spectrum of strides that are moving the field of immunotherapy forward to improve long-term survival for patients.”

Isabella Glitza Oliva, MD, PhD, of The University of Texas MD Anderson Cancer Center will highlight the McGraw clinical trial findings during her Nov. 11 presentation, “Evaluation of the Safety and Efficacy of an Oral Microbiome Intervention (SER-401) in Combination with Nivolumab in First Line Metastatic Melanoma Patients” (Abstract 607). She is scheduled to present at 5:05 p.m. Eastern Standard Time (EST) in Room 153ABC of the convention center during Concurrent Session 214.

Also on Nov. 11, PICI member Padmanee Sharma, MD, PhD, (Twitter: @PamSharmaMDPhD) of MD Anderson will deliver the keynote address, “From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy.” She will speak at 8:25 a.m. EST in Hall B2.

Sharma is one of five members of the meeting organizing committee and is chair of the programming committee.

Below is information on the other PICI-led clinical trials. Findings from the studies will be presented as posters at the noted times (all EST). All abstracts are available Nov. 7.

Nov. 10, 9 a.m.-9 p.m.
Boston Convention & Exhibition Center, Hall C

Clinical Trial Presentation
PORTER Title: “Clinical and Pharmacodynamic Biomarker Results from PORTER, a multi-cohort Phase 1 Platform Trial of Combination Immunotherapy for Metastatic Castration-Resistant Prostate Cancer Patients” (Abstract 555)

Title: “Biomarker Correlates of Clinical Response with FLT3L/Nivo Backbone Treatment in the Multi-Cohort Phase 1 PORTER Platform Trial in Metastatic Castration-Resistant Prostate Cancer Patients” (Abstract 559)

AMADEUS Title: “Tumor Agnostic Pre- and On-treatment Biomarkers of Response to Nivolumab Plus Ipilimumab Correlate with On-treatment Tumoral T cell Infiltration” (Abstract 587)
BRUCE Title: “Spatial-transcriptomic Analysis of Neoadjuvant Checkpoint Immunotherapy in Recurrent Glioblastoma” (Abstract 643)

Nov. 11, 9 a.m.-8:30 p.m.
Boston Convention & Exhibition Center, Hall C

Clinical Trial Presentation
REVOLUTION Title: “Exploratory Platform Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma” (Abstract 656) 
RADIOHEAD Title: “Relationships Between irAEs and Checkpoint Inhibitor Response in RADIOHEAD: A Large Prospective Pan-tumor Cohort of Standard-of-care Patients with Clinical Annotation, Molecular and Immune Profiling” (Abstract 1256)
MORRISON Title: “A Reproducible Pipeline for Analysis of Multiplex Imaging (MIBI) Data with Application to Uncovering Novel Features of the Tumor-immune Microenvironment” (Abstract 1292) 
NANOSTRING Title: “First data readout of standardized transcriptional profiling for optimizing cellular therapies: A Multi-Center PICI-NanoString collaboration ” (Abstract 1468) 

Below are additional select sessions featuring PICI Network investigators who are presenting other findings or are moderating sessions. Please note that listings are subject to change. For the most current information, visit the event schedule. For more information, please email press@parkerici.org

Follow the meeting live on Twitter using the hashtag #SITC22.

PRE-CONFERENCE PROGRAMS 

Omni Boston Hotel
Rooms to be announced 

Nov. 9, 2022
All times EST

Primer on Tumor Immunology and Cancer Immunotherapy
Session I – Introduction to Immunology: Generating Effective Anti-Tumor Immunity

8:05-9:45 a.m.

8:45 a.m. Title: “Modeling Adaptive Immune Responses to Cancer in the Mouse” 

Presenter: Robert D. Schreiber, PhD, Washington University School of Medicine in St. Louis

Session III – Approaches to Immunotherapy: Driving T Cells to the Tumor

1:15-3 p.m.

1:20 p.m. Title: “Developing Personalized Cancer Vaccines” 

Presenter: Catherine J. Wu, MD, Dana-Farber Cancer Institute

 

Combination Therapy: Applying Learnings from Past Successes and Failures to Future Treatments
Session I – Cellular Targets of Combination Therapies

9-10:35 a.m.

9:05 a.m. Title: “Role of T cell Exhaustion Biology in Cancer Immunotherapy” 

Presenter: E. John Wherry, PhD, University of Pennsylvania (Twitter: @EJohnWherry)

Session II – Mediators of Immune Inhibition

10:45 a.m.-1:45 p.m.

Moderator: Philip D. Greenberg, MD, Fred Hutchinson Cancer Center

Session III – Immunotherapy Combination Strategies

1:45-3:15 p.m.

2:15 p.m. Title: “Synthetic Biology in the Age of Cell-based Immunotherapy”

Presenter: Yvonne Chen, PhD, University of California, Los Angeles

ANNUAL MEETING
Boston Convention & Exhibition Center 

Nov. 10
All times EST

Session 101 – Richard V. Smalley Memorial Award and Lectureship

8-8:50 a.m., Hall B2

8:05 a.m. Panel Honoring the Work of Zelig Eshhar, PhD 

Panelists include: 

Session 102 – Biomarkers

8:55-11:05 a.m., Hall B2

9:20 a.m. Title: “Multi-omic Single-cell Discrimination of Immunotherapy-induced Immune Responses” 

Presenter: Lawrence Fong, MD, University of California, San Francisco (Twitter: @lawfong)

Concurrent Session 104 – Rapid Oral Abstracts – Basic Science

11:55 a.m.-12:55 p.m., Room 253ABC

12:25 p.m. Title: “Landscape Analysis of the Neoepitope-specific T cell Responses in Patients with and without Clinical Benefit from Immune Checkpoint Blockade Therapy” (Abstract 123) 

Presenter: Cristina Puig Saus, PhD, (Twitter: @PuigSaus) University of California, Los Angeles

Session 1081 – Pre-clinical/Model Systems vs. Human

3:20-4:30 p.m., Hall B2

Co-chair: Robert D. Schreiber, PhD

3:35 p.m. Title: “Use of High Dimensional Transcriptomic, Proteomic and Spatial Profiling in Mouse Tumor Models of Cancer Immunotherapy and the Applicability of These Studies to Understanding Naturally Occurring and Therapeutically Induced Human Responses to Cancer” 

Presenter: Robert D. Schreiber, PhD

3:45 p.m. Title: “Cellular Therapies” 

Presenter: Philip Greenberg, MD

Concurrent Session 110 – Bias & Diversity in Cancer Research

4:40-5:55 p.m., Room 258ABC

Co-chair: Avery D. Posey, PhD, (Twitter: @IAmDrDex) University of Pennsylvania

Concurrent Session 113 – Cellular Therapies + Bispecifics

4:40-5:55 p.m., Ballroom East

Co-chair: Yvonne Chen, PhD

5:02 p.m. Title: “Bispecific BiTEs” 

Presenter: David Miklos, MD, Stanford University

Concurrent Session 114 – Abstract Session

4:40-5:55 p.m., Room 153ABC

4:55 p.m. Title: “Immunogenic Landscape and Therapeutic Targeting of Mutant NRAS ‘Public’ Neoantigens” (Abstract 218) 

Presenter: Inaki Etxeberria, PhD, (Twitter: @etxeberria_i) Memorial Sloan Kettering Cancer Center

Concurrent Session 116 – Cancer Immunotherapy in Special Patient Populations

6:05-7:20 p.m., Room 253ABC

Co-chair: Crystal Mackall, MD

Concurrent Session 119 – Vaccines: In Situ Agents and Novel Systemic Approaches

6:05-7:20 p.m., Room 205ABC

Co-chair: Dmitriy Zamarin, MD, PhD, Memorial Sloan Kettering Cancer Center

Nov. 11
All times EST

Session 203 – Immunotherapy in Early-stage Disease

9:35-11:20 a.m, Hall B2

Co-chair: Elizabeth A. Mittendorf, MD, PhD, Dana-Farber Cancer Institute

Concurrent Session 216 – Convergence Towards Enhanced Immunotherapy

5:40-6:25 p.m., Room 210ABC

5:40 p.m. Title: “Computational Deconstruction of Neoantigen-TCR Degeneracy for Cancer Immunotherapy”

Co-presenter: Vinod Balachandran, MD, (Twitter: @TheVinodLab) Memorial Sloan Kettering Cancer Center

5:55 p.m. Title: “Connecting Immune Health and Tumor Biology in Gynecologic Cancers” 

Presenter: Claire Friedman, MD, (Twitter: @ClaireFriedma19) Memorial Sloan Kettering Cancer Center

Nov. 12
All times EST

Session 301 – Resistance to Checkpoint Blockade Immunotherapy

8:05-9:45 a.m., Hall B2

Co-chair: Padmanee Sharma, MD, PhD

Session 302 – Thomas Waldmann Memorial Plenary Session: New Immunotherapies

9:55-11:25 a.m., Hall B2 

Co-chair: Andrea Schietinger, PhD, (Twitter: @SchietingerLab) Memorial Sloan Kettering Cancer Center

Session 303 – Hot Topic Symposium: When Phase 3 Trial Results Diverge from Phase 2 Data – An Analysis of Recent Trials in Immuno-oncology

11:35 a.m.-1:05 p.m., Hall B2

 

 

11:35 a.m. Title: “Melanoma Failed CPI Trials (IDO, TVEC, BEMPEG, Idura, Combi I, IMSpire)” 

Presenter: Adil Daud, MD, (Twitter: @ad1600) University of California, San Francisco